GLOBAL ENGAGE’S 3 MICROBIOME R&D AND …€¦ · a therapeutics market that is expected to grow to $1.2 trillion by 2016, ... Yakult Danone India Pvt. Ltd. ... • Feed additives

1-2 March 2017HONG KONG

MICROBIOME R&D AND BUSINESS COLLABORATION CONGRESS

COLLABORATIONS IN MICROBIOTA RESEARCH, LIVE BACTERIAL THERAPEUTICS, HUMAN HEALTH & DISEASE

GLOBAL ENGAGE’S 3RD

PROBIOTICS CONGRESSRESEARCH, DEVELOPMENT & APPLICATION OF PROBIOTICS AND PREBIOTICS IN HUMAN AND ANIMAL HEALTH

GLOBAL ENGAGE’S 2ND

www.global-engage .com #GEMB17

WARM WELCOME

Thank you for your interest in the 3rd Global Engage Microbiome R&D and Business Collaboration Forum and Probiotics Congress. As part of its international microbiome series, Global Engage is pleased to announce the co-located event which will be held on 1-2 March, 2017 in Hong Kong.

Developments in the field of metagenomics have allowed researchers to explore the diverse microbiota in the human body. Research has shown that the microbiome is linked to natural immunity, metabolism, behavioural traits, and broadly speaking, plays an instrumental role in health and disease. With large-scale collaborative projects underway and sequencing data placed in the public domain, there is a rich source of information for researchers and companies looking for opportunities in this exciting field. Increasingly, there are indications that the human microbiome is key to curative and preventative medicine, so efforts are being focused on expanding investment opportunities, performing more clinical trials and spurring innovative research in this area. Coupled with an increasing focus on healthy living, and a therapeutics market that is expected to grow to $1.2 trillion by 2016, microbiome research is set to make waves in the science and medical world through its applications in preventative treatments, cures, therapies and supplements.

Attracting over 250 attendees, the 10th meeting in the global series will build upon the success of last year’s meeting which attracted over 200 attendees as well as on our highly popular European and American forums. Bringing together experts in all areas of microbiome and probiotics research, the congress will explore the interface between the microbiome and our evolving cultures and technologies as well as the development of next generation probiotics, prebiotics and functional foods. During the two-day conference, there will be networking breaks to promote interaction with your peers, expert led case study presentations, a dynamic exhibition room filled with technology providers showcasing their technologies and solutions, and panel discussions exploring key issues in the field. Together, we can further develop microbiome and probiotics research across the Asia-Pacific region, and begin to look towards forging collaborations and commercializing the research.

YUAN KUN LEEAssociate Professor, Department

of Microbiology, National University of Singapore

PHILIP HUGENHOLTZDirector, Australian Centre for

Ecogenomics; Professor, School of Chemistry & Molecular

Biosciences, The University of Queensland, Australia

LARRY WEISSChief Medical Officer, AOBiome, LLC, USA

NEERJA HAJELAGeneral Manager – Science and Regulatory Affairs, Yakult Danone

India Pvt. Ltd.

EXPERT SPEAKERS Include:

MICROBIOME R&D AND BUSINESS COLLABORATION / PROBIOTICS CONGRESS ASIA 2017

CONFERENCE SYNOPSIS

GUT MICROBIOTA IN HEALTH AND DISEASE

• Updates on the Asian gut microbiome project• Novel models for studying gut-microbe interactions• Connections to IBD, IBS and diarrheal diseases• Fecal transplantation• Innate immune system and host-pathogen interaction• Associations with obesity and metabolic disease• The virome and its role in health and disease• Role of synthetic biology• Gnotobiotic mice studies• Gut-brain interactions – depression, anxiety and autism?• Development of bacteriophage therapeutics• Metagenomics – microbiome sequencing and bioinformatics

SKIN, ORAL AND VAGINAL MICROBIOTA

• Diversity of skin communities• Interactions between host genotype and microbial abundances• Skin and scalp microbiomes• Case studies and therapeutic potential in acne, eczema, atopic

dermatitis, and microbiomes of chronic and acute wounds• Oral cancer associated microbiome• Microbiome of the female urogenital tract and pregnancy• Research into the microbiome and HIV

PREBIOTICS AND DIET

• Dietary modulation of the human gut microbiome• Gut microbiota in varying nutritional states• Role of short-chain fatty acids• Milk-oriented microbiota• Developing nutritional products utilising microbiome research

COMMERCIALIZATION OF THE MICROBIOME & PROBIOTICS

• Collaborations/partnerships – the global scope of microbiome research/structuring successful collaborations

• Bringing live microbial products to market – IP, regulation• Bugs as drugs – microbiome therapeutic development• Contemplating novel antibiotic therapies that do not destroy the

healthy microbiome• Probiotic strain identification, designation and safety

PROBIOTICS AND DISEASE

• Probiotics and digestive health• Probiotics in pediatrics• Probiotics and dietary interactions

PROBIOTICS IN WOMEN’S HEALTH

• Reducing the recurrence of urogenital infections in women• Probiotics in bacterial vaginosis• Vaginal microbiome

PROBIOTICS FOR ANIMAL HEALTH

• Feed additives to target disease• Antibacterial resistance• Aquaculture, companion and production animals

PANEL DISCUSSIONS

• What is a healthy, balanced microbiome? How important is gut microbial diversity?

• Current research and future developments in animal probiotics

UNABLE TO MAKE THE HONG KONG DATES? Why not sign up for either our European or US meeting

Europe: 3-4 April 2017 – Amsterdamwww.global-engage.com/event/microbiota/

USA: 2-3 November 2017 – San Diegowww.global-engage.com/event/microbiome/


EVENT SPONSORS

Gold Sponsors 2017

Exhibitors 2017


Silver Sponsors 2017

Sponsors 2017

CONFIRMED MICROBIOME SPEAKERS


HIROSHI OHNOGroup Director, Laboratory for Intestinal Ecosystem, RIKEN Center for Integrative Medical Sciences (IMS), Japan

YUAN KUN LEEAssociate Professor, Department of Microbiology, National University of Singapore

G. BALAKRISH NAIRAg Regional Advisor, Research Policy Cooperation Unit, Communicable Diseases Department, World Health Organization, India

MARGARET MORRISProfessor, Chair and Head of Pharmacology, School of Medical Sciences, University of New South Wales, Australia

HEENAM STANLEY KIMProfessor, College of Medicine, Korea University

LARRY WEISSChief Medical Officer, AOBiome, LLC, USA

CHRISTOPHE LAYSenior Scientist Gut Microbiology, Life Science Innovation – Early Life Nutrition, Danone Nutricia Research, Singapore

SABINA LUKOVACSenior Project Leader Microbiomics, Department of Health, NIZO Food Research, The Netherlands

PHILIP HUGENHOLTZDirector, Australian Centre for Ecogenomics; Professor, School of Chemistry & Molecular Biosciences, The University of Queensland, Australia

HONGWEI ZHOUProfessor, Director, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, China

AARON DEL DUCAVP Technology & Lead, Microbiome Program, DNA Genotek, Inc.

LYNNETTE FERGUSONDirector of Mutagen Testing, Auckland Cancer Society Research Centre (ACSRC) & Professor of Nutrition, The University of Auckland, New Zealand

COLLEEN CUTCLIFFECo-Founder & CEO, Whole Biome, USA

PETER CHI KEUNG CHEUNGProfessor, School of Life Sciences, Director, Food and Nutritional Science Program, Chinese University of Hong Kong

YOSHIHISA YAMASHITAProfessor & Chairperson, Section of Preventive and Public Health Dentistry, Kyushu University, Japan

GILDA TACHEDJIANAssociate Professor & Principal for Sexual and Reproductive Health, Head Retroviral Biology and Antivirals Laboratory, Burnet Institute, Australia

YUNN-HWEN GANAssociate Professor, Department of Biochemistry, National University of Singapore

NIRANJAN NAGARAJANAssociate Director and Group Leader, Genome Institute of Singapore, A*STAR, Singapore

ELIANA MARIÑOHead, Immunology and Diabetes Laboratory, Monash University, Melbourne, Australia

NICOLE ROYPrincipal Scientist and Science Team Leader, Food Nutrition & Health, AgResearch Grasslands, Adjunct Associate Professor, Riddet Institute, Massey University, New Zealand

KIYOSHI TAKEDAProfessor, Graduate School of Medicine, Osaka University, Japan

DAVID WOODPostdoctoral Research Officer, School of Chemistry and Molecular Biosciences, Australian Centre for Ecogenomics, The University of Queensland, Australia

SIEW NGProfessor, Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong

JASNA RAKONJACAssociate Professor, Institute of Fundamental Sciences, Massey University, Palmerston North, New Zealand

BOWEN ZHAOFounder & CEO, QuantiHealth, China

MARGARET IPProfessor, Department of Microbiology, The Chinese University of Hong Kong

RUI LISenior Scientist, Procter & Gamble, Singapore

ERIC HUANG Professor, Department of Dermatology, University of California, San Diego, USA

NICHOLAS WESTResearch Fellow, Mucosal Immunology Research Group, Griffith University, Australia

LOUISE VIGSNAESPreclinical Development Manager, Glycom A/S, Denmark

DAVID J. KYLECEO, Evolve BioSystems

PETER VUILLERMINAssociate Professor in Paediatrics, School of Medicine, Deakin University, Australia

DIETER BULACHSenior Research Scientist, Victorian Life Science Computation Initiative, The University of Melbourne, Victoria, Australia

JIAN-YONG WU (TRACK CHAIR)

Associate Professor, Department of Applied Biology & Chemical Technology, The Hong Kong Polytechnic University

KENNETH GAOManager, Corporate Development and Strategy, Assembly Biosciences, Inc., USA

JONATHAN KRIVECEO, Civet Biosciences, Hong Kong

CONFIRMED PROBIOTICS SPEAKERS

GORDON HOWARTHProfessor of Gastrointestinal Physiology, School of Animal and Veterinary Sciences, University of Adelaide, Australia

PATRICIA CONWAYProfessor, School of Biological, Earth and Environmental Sciences, UNSW Australia

HAU YANG TSENProfessor of Food Science and Technology, Hungkuang University, Taiwan

ROBERT MOOREResearch Professor of Biotechnology, RMIT University, Melbourne, Australia

KANWALDEEP CHADHAVice President, Next Gen Pharma India Pvt. Ltd.

YING-CHIEH TSAIProfessor, National Yang Ming University, Taiwan

ŞEBNEM HARSA (TRACK CHAIR)Professor, Faculty of Engineering, Food Engineering Department, İzmir Institute of Technology, Turkey

HARJINDER SINGHDistinguished Professor and Director, Massey Institute of Food Science and Technology, Massey University, New Zealand

NAGENDRA SHAHProfessor of Food Science and Technology, Discipline Leader, Food and Nutritional Sciences, School of Biological Sciences, The University of Hong Kong

SEAN HALLMD, MBA, CFEO/MD – Medlab Clinical Ltd, Australia

HANI EL-NEZAMIAssociate Professor, School of Biological Sciences, The University of Hong Kong

SUNEE NITISINPRASERT Associate Professor, Department of Biotechnology, Faculty of Agro-Industry, Kasetsart University, Thailand

RAMA CHAUDHRYASM International Ambassador to India; Professor, Department of Microbiology, All India Institute of Medical Sciences, India

ROSHADA HASHIMProfessor, Fish Nutrition and Feeding Management, Faculty of Science and Technology, Universiti Sains Islam Malaysia

INGRID SURONO(TRACK CHAIR)Head of Food Technology Department, Binus University, Indonesia

STEPHEN OHARAFounder and CEO, OptiBiotix Health plc

YASUHIRO KOGAProfessor, Tokai University School of Medicine; President, Japanese Society for Probiotic Science, Japan

MOHD REDZWAN SABRAN Senior Lecturer, Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia

NEERJA HAJELAGeneral Manager – Science and Regulatory Affairs, Yakult Danone India Pvt. Ltd.

PRAMOD GOPALScience Group Leader, Food, Nutrition & Health, The NZ Institute for Plant & Food Research Ltd.

SHIVANANDA MURTHYProfessor & Head, Karnataka Veterinary & Fisheries Sciences University, College of Fisheries, Mangalore, India

RINA AGUSTINAScientist, Southeast Asian Ministers of Education Organization Regional Center for Food and Nutrition

(SEAMEO RECFON) / Pusat Kajian Gizi Regional (PKGR), Universitas Indonesia, Head of Human Nutrition Research Cluster and Research Coordinator Department of Nutrition, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital, Indonesia

KIYOSHI TAKEDAProfessor, Graduate School of Medicine, Osaka University, JapanRegulation of intestinal homeostasis by a colonic epithelial molecule, Lypd8Separation of intestinal microbiota and colonic epithelia is essential for the maintenance of intestinal homeostasis. However, its mechanism remained unknown. We demonstrated that Ly6/PLAUR domain containing 8 (Lypd8) was secreted

into the colonic lumen, bound to flagella of intestinal bacteria, and inhibited their motile activity. We also found that the Lypd8-dependent suppression of bacterial motility was required for prevention of intestinal inflammation. Thus, Lypd8 is essential for the maintenance of intestinal homeostasis.

CONGRESS SCHEDULE DAY 1 WEDNESDAY 1ST MARCH 2017

Registration & Refreshments09

:00-

09:3

5

KEYNOTE ADDRESS:PHILIP HUGENHOLTZDirector, Australian Centre for Ecogenomics; Professor, School of Chemistry & Molecular Biosciences, The University of Queensland, AustraliaCommon but uncharacterised microbial populations in the healthy human gut development?

The structure and function of the human gut microbiome is rapidly being revealed through culture-independent molecular techniques. Despite a great deal of interpersonal variability due to factors such as diet, age and ethnicity, there are a small number of relatively abundant microbial species that are widespread in the human population. Some of these are well known, such as Faecalibacterium prausnitzii, but others are as yet uncultured and uncharacterised. In this talk, I will introduce the audience to some of the lesser-known but potentially important members of the healthy human gut microbiome.

08:00-08:50

08:50-09:00 Global Engage Welcome Address and Morning Chair’s Opening Remarks: Peter Vuillermin, Associate Professor in Paediatrics, School of Medicine, Deakin University, Australia

10:0

0-10

:30

09:3

5-10

:00

09:3

5-10

:00

KEYNOTE ADDRESS:NAGENDRA SHAHProfessor of Food Science and Technology, Discipline Leader, Food and Nutritional Sciences, School of Biological Sciences, The University of Hong KongCurrent trends in probiotics and prebioticsThe term “nutraceutical” combines two words – “nutrient” and “pharmaceutical”. The

philosophy behind nutraceuticals is to focus on prevention. Dietary supplement is a product that contains nutrients derived from food products that are concentrated in liquid or capsule form. Foods can be modified by the addition of phytochemicals, bioactive peptides, n-3 polyunsaturated fatty acids, and addition of probiotics and prebiotics in order to become functional. This presentation will highlight nutraceuticals/functional foods based on probiotics and prebiotics, milk protein and whey proteins, nutritional properties of whey proteins, roles of whey proteins and bioactive from whey proteins, lactoferrin, whey protein products in sports nutrition, and bioactive peptides and their release and functional properties. The presentation will also cover current trends in nutraceuticals and finally future perspectives of nutraceuticals.

09:0

0-09

:35

SOLUTION PROVIDER PRESENTATION:BOWEN ZHAOFounder & CEO, QuantiHealth, ChinaAn integrated solution for microbiota testingMicrobiota Testing has been considered challenging, due to

• complicated nature of microbiota samples,• absence of standardized sampling-storage solution,

• and lack of analytic tools for precision modeling and automated analyses.QuantiHealth provides an integrated solution designed for Microbiota Testing (and intervention in the near future), featuring

• a professional fecal sampling-transportation-storage AIO solution,• LinEnrich™, a target-region microbiome quantification method,• and KnowledgeBase™, a cloud-based automated analytic platform,

The Human Symbiotic Microbial Seed Bank under construction will also be introduced.

Morning Refreshments / Even Numbered Poster Presentations & Scheduled One-to-One Meetings10:30-11:40

Global Engage Welcome Address and Morning Chair’s Opening Remarks:08:50-09:00

NEERJA HAJELAGeneral Manager – Science and Regulatory Affairs, Yakult Danone India Pvt. Ltd.Antibiotic resistance and probiotics – a metagenomic view pointAntibiotics have been the greatest discovery of the 20th century and have played a significant role in reducing the global burden of infectious diseases. However, their extensive and inappropriate use has resulted in emergence of Anti - Microbial Resistance (AMR)

which has threatened the ability to treat disease. Several lines of evidence confirm that antibiotic administration can result in intestinal microbiota dysbiosis. The alteration in the intestinal microbiota has been associated with atopic, inflammatory and autoimmune disorders and an increased susceptibility to disease. Probiotics that can favourably modulate and stabilize the intestinal microbiota and provide colonization resistance against pathogenic organisms are an excellent means of remediation and deterrence against a variety of intestinal disorders and extra-intestinal infections. Decades of research have identified some promising gastrointestinal and immune targets for probiotics that include maintenance of a healthy intestinal function, improved tolerance to antibiotics and an overall reduced risk for different chronic diseases. The renewed interest in probiotics brings new hope for defeating disease causing bacteria while limiting collateral damage to the microbiota.


CONGRESS SCHEDULE


11:4

0-12

:05

11:4

0-12

:05

HEENAM STANLEY KIMProfessor, College of Medicine, Korea UniversityFaecalibacterium prausnitzii dynamics in the human gut microbiome underlying atopic dermatitisAlthough decades of research have stressed

the significance of dysbiosis in the gut microbiota in atopic dermatitis (AD), the specific microbial dysfunction adversely affecting the regulation of inflammation underlying AD remained unknown. We recently discovered that subspecies-level dysbiosis in Faecalibacterium prausnitzii is strongly associated with AD. Our results provide lines of evidence supporting that subspecies-level dysbiosis in F. prausnitzii and inflammation in the gut epithelial layer are mutually stimulatory, and the establishment of this feedback loop is the basis of the chronic nature of AD, ultimately leading to aberrant immune responses to allergens in the skin. These results demonstrate the significance of the competitive dynamics among the bacteria within the same species in the microbiota, affecting the function of the entire microbiota.

11:4

0-12

:05

DAY 1 WEDNESDAY 1ST MARCH 2017

12:0

5-12

:30

12:0

5-12

:30

NIRANJAN NAGARAJANAssociate Director and Group Leader, Genome Institute of Singapore, A*STAR, SingaporeThe role of the skin microbiome in eczemaThe human skin is our primary protection against environmental and pathogenic insults. Despite

our best efforts to eradicate them, our epidermis harbours a complex microbial ecosystem. Different parts of the body offer widely different environments, the equivalent of variation from rain-forests to deserts for bacterial communities. While most skin residents are harmless or beneficial to the host, some can lead to skin diseases. In particular, eczema is a common skin condition (15-30% of children and 2-10% of adults) where the interaction between microbes and the host immune system is believed to play a role. Eczema (or Atopic Dermatitis; AD) has a significant impact on quality of life of affected individuals and increasing healthcare and other associated costs worldwide. Using modern genomic techniques and the first metagenome-wide association study on skin we have identified key perturbations in the resident skin microflora that could act as triggers for AD flares. This analysis suggests that individuals with eczema harbour a distinct community that is primed for pathogen growth and inflammation. We propose a new form of the hygiene hypothesis for explaining the increasing incidence of eczema, revealing in the process novel therapeutic targets for this disease.

12:0

5-12

:30

GORDON HOWARTHProfessor of Gastrointestinal Physiology, School of Animal and Veterinary Sciences, University of Adelaide, AustraliaIdentification of new probiotics utilizing animal models and non-invasive breath tests

Increasingly, dysbiotic characteristics are being associated with a range of gastrointestinal disorders including the inflammatory bowel diseases, ulcerative colitis and Crohn’s disease; as well as a range of other bowel conditions such as chemotherapy-induced mucositis and colon cancer. Animal models of these disorders provide a viable tool to test and identify new probiotic species able to restore microbiota homeostasis and intestinal integrity. This presentation will describe utility of animal model systems to identify new clinically-applicable probiotic species. Moreover, the application of new breath-testing techniques to these models enables a range of gastrointestinal functions to be determined non-invasively by the simple collection of expired breath.

HIROSHI OHNOGroup Director, Laboratory for Intestinal Ecosystem, RIKEN Center for Integrative Medical Sciences (IMS), JapanThe impact of gut microbiome on the pathogenesis of experimental autoimmune encephalomyelitis in mice, a model of multiple sclerosis

• Pathogenesis of experimental autoimmune encephalomyelitis (EAE) is affected by the gut microbiota composition.

• Small intestinal bacteria affect the EAE pathogenesis by inducing Th1 and Th17 cells in the small intestinal lamina propria.

• A combination of bacteria, rather than a specific stain of bacterium, seems to play a role in the strong induction of EAE.

YING-CHIEH TSAIProfessor, National Yang Ming University, TaiwanMicrobiota-gut-brain axis and psychobiotics: Lactobacillus plantarum PS128 as an exampleGut-brain axis is evidenced to play important roles in

physical and mental health. Gut microbiota show impacts on brain development and host behavior through a bidirectional communication system between the gut microbiota, the brain the microbiota-gut-brain axis. Psychobiotics, a class of probiotics with psychotropic activities, integrates neural, hormonal, and immunological signaling via gut-brain axis is proved for combating a broad spectrum of complex diseases including mental illness, irritable bowel syndrome (IBS), neurodegenerative disorders and neurodevelopmental disorders. Lactobacillus plantarum PS128 (PS128) was identified and found to normalize depression-like behaviors in early life-stressed mice and to increase locomotor activity in Parkinson’s disease-like mice. PS128 reduced the 5-HTP-induced visceral hypersensitivity in a rat model of IBS and reversed the 5-HT(2A/2C) agonist 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) induced Tourette syndrome-like responses in rats. In the above studies, alteration of the stress hormone, corticosterone, neurotransmitters, dopamine, serotonin and substance P, and neurotrophins, brain derived neurotrophic factor and nerve growth factor, were observed. The results of behavioral tests and neural molecules analysis demonstrate that psychobiotic PS128 could be a potent alternative for neuropsychiatric disorder

G. BALAKRISH NAIRAg Regional Advisor, Research Policy Cooperation Unit, Communicable Diseases Department, World Health Organization, IndiaThe interplay of enteric pathogens in the gut microbiota of children and adults

The human gastrointestinal tract, the major site of nutrient assimilation and micronutrient production, is populated with trillions of microbial species from all three domains of life (Archaea, Bacteria and Eukarya). Several species of commensal bacteria play important role in synthesis of essential micronutrients and other metabolites, which are the key components for the maintenance of human health. Pathobionts, in turn, have developed maneuvers to escape the protective influence of commensal bacteria. The interplay between pathobionts and commensals can also impact host physiology. Our studies attempt to understand the prevalence, diversity, and abundance of low-abundant pathobionts in the gut microbiota of children and adults. We believe that these findings may lead to new insights into examining their involvement in human physiology and the significance of their low-abundance presence in the gut microbiota.

GUT MICROBIOTA IN HEALTH & DISEASE MICROBIOTA & SKIN CONDITIONS PROBIOTICS CONGRESS

TRACK CHAIR:ERIC HUANGProfessor, Department of Dermatology, University of California, San Diego, USA

TRACK CHAIR:PETER VUILLERMINAssociate Professor in Paediatrics, School of Medicine, Deakin University, Australia

12:3

0-13

:00

PANEL DISCUSSION:What is a healthy, balanced microbiome? How important is gut microbial diversity?

PANEL CHAIR:YUAN KUN LEEAssociate Professor, Department of Microbiology, National University of Singapore

CONFIRMED PANELLISTS:PHILIP HUGENHOLTZDirector, Australian Centre for Ecogenomics; Professor, School of Chemistry & Molecular Biosciences, The University of Queensland, Australia

CHRISTOPHE LAYSenior Scientist Gut Microbiology, Life Science Innovation – Early Life Nutrition, Danone Nutricia Research, Singapore

KENNETH GAOManager, Corporate Development and Strategy, Assembly Biosciences, Inc., USA

12:3

0-13

:00



12:3

0-13

:00

ERIC HUANGProfessor, Department of Dermatology, University of California, San Diego, USAZymologic editing of skin dysbiotic microbiome A Skin Probiotic Bacteria Bank with more

than fifty fermenting skin bacteria for treatment of twenty skin disorders has been established in our laboratory. Carbohydrates, polyethylene glycol (PEG) macromers and their conjugates were synthesized as selective fermentation initiators (SFIs) for specifically enhancing the fermentation (zymological) activities of skin probiotic bacteria. Acne dysbiosis occurs when there is a microbial imbalance of the over-growth of Propionibacterium acnes (P. acnes) in the acne microbiome. We have identified several SFIs which can selectively promote the zymological activities of skin probiotic bacteria against P. acnes. Unlike live microorganisms (eg bacteriophages), SFIs are used as non-microorganism agents for editing dysbiotic skin microbiome.

MOHD REDZWAN SABRANSenior Lecturer, Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra MalaysiaDietary approach using probiotics to prevent human exposure to aflatoxin

• Human dietary aflatoxin exposure is ubiquitous and probiotics are used to prevent the absorption of aflatoxin in the gastrointestinal tract

• Probiotics act as biological barrier by binding aflatoxin into the bacterial cell walls

• Findings from animal and human intervention studies showed the potential use of probiotics as a detoxification agent of aflatoxin.

13:0

0-13

:30

SOLUTION PROVIDER PRESENTATION:NICHOLAS WESTResearch Fellow, Mucosal Immunology Research Group, Griffith University, AustraliaProbiotics for allergy care: growing evidence of benefitThe benefit of probiotics is based on growing knowledge that the gut microbiota plays an important role in health and disease. Reduced microbial diversity is considered a key factor in the increase in allergies observed in developed countries. The World Allergy Organisation recommends the use of probiotics for the primary prevention of eczema while clinical trial evidence indicates a moderate

benefit for allergy in a number of population groups. This talk will review the latest research on the use of probiotics for allergy, limitations to the research and whether sufficient evidence is available for clinical recommendations on the use of probiotic supplements in allergy.

Lunch13:30-14:30


14:3

0-14

:55

14:3

0-14

:55

DAVID WOODPostdoctoral Research Officer, School of Chemistry and Molecular Biosciences, Australian Centre for Ecogenomics, The University of Queensland, AustraliaA natural history of the actinic keratosis microbiome in immunocompetent men

Actinic keratosis is a condition where pre-malignant lesions develop on sun-damaged skin, and if untreated, a small percentage progress to cutaneous squamous cell carcinoma (cSCC). Human skin hosts resident bacterial and fungal populations that may be associated with AK and cSCC. We applied culture-independent community profiling and shotgun metagenomics to longitudinally investigate the AK and cSCC microbiome in a cohort of ten immunocompetent men with a history of cSCC. Our results indicate highly patient-specific communities and taxa significantly associated with AK and cSCC lesions and also different taxa associated with non-lesional skin. These findings indicate the personalised nature of AK lesion pathology, and may aid in the treatment of AK and subsequent cSCC lesions.

14:3

0-14

:55

LYNNETTE FERGUSONDirector of Mutagen Testing, Auckland Cancer Society Research Centre (ACSRC) & Professor of Nutrition, The University of Auckland, New ZealandCan we modify the microbiome of an inflammatory bowel disease population using a dietary supplement without prebiotics or recognised probiotics?


TRACK CHAIR:ERIC HUANGProfessor, Department of Dermatology, University of California, San Diego, USA

TRACK CHAIR:ŞEBNEM HARSAProfessor, Faculty of Engineering, Food Engineering Department, İzmir Institute of Technology, Turkey

TRACK CHAIR:YUNN-HWEN GANAssociate Professor, Department of Biochemistry, National University of Singapore

GUT MICROBIOTA IN HEALTH & DISEASE MICROBIOME R&D PROBIOTICS CONGRESS

HARJINDER SINGHDistinguished Professor and Director, Massey Institute of Food Science and Technology, Massey University, New ZealandTechnological challenges for enhancing the stability of probiotic bacteria in functional foods

Probiotic bacteria have been increasingly added to various foods. To achieve a significant benefit of probiotics, we need to consume relatively high number of live bacteria (108 – 109 CFU/day), which need to reach the intestine safely in a viable state. However, probiotics when administered as a part of food product experience many unfavourable conditions, such as adverse processing parameters (heating, low pH, oxygen etc.), and exposure to gastric acid in the stomach and bile salts in the intestine. Therefore the incorporation of probiotics into functional foods presents a formidable challenge, primarily in terms of shelf-life and viability through to time of consumption. Traditionally, chilled dairy products have been the main formats for delivery of probiotics in foods. Incorporation of probiotic bacteria into food products that are stored at room temperature creates an overwhelming challenge for probiotic stability. The presentation will mainly focus on recent approaches for stabilization of probiotic cells to deliver probiotics through shelf stable foods.

PETER VUILLERMINAssociate Professor in Paediatrics, School of Medicine, Deakin University, AustraliaThe maternal microbiome during pregnancy and offspring allergic disease and asthma

Evidence from animal models suggest that a maternal diet high in microbiota accessible carbohydrates (MACs) may be associated with decreased offspring allergic disease and asthma. However the relevance of these findings to humans remains uncertain. The Barwon Infant Study (BIS) is the only extant birth cohort to combine the assembly of maternal dietary data and faecal samples during pregnancy with detailed phenotyping of offspring immune function, allergy status (including challenge proven food allergy), lung function and respiratory health. In this session Prof Vuillermin will present exciting findings from BIS regarding the relationship between the maternal diet and microbiome during pregnancy and offspring allergic disease.

14:5

5-15

:20

14:5

5-15

:20

14:5

5-15

:20

DIETER BULACHSenior Research Scientist, Victorian Life Science Computation Initiative, The University of Melbourne, Victoria, AustraliaUsing whole metagenome sequencing (WMS) to investigate the onset of Bacterial Vaginosis

• An outline of the WOW study led by Dr Catriona Bradshaw healthy BV specimens

• Overview of microbial communities present in specimens from WOW study using 16s gene sequencing

• Use of these data to select specimens for WMS• Outline of analysis strategy used to investigate WMS data sets

with emphasis on evaluation of Gardnerella genetic types present in specimens

PATRICIA CONWAYProfessor, School of Biological, Earth and Environmental Sciences, UNSW AustraliaThe role of probiotics in infant health and well-beingThe composition and function of the developing

gut microbiome of the infant has huge ramifications for the health and well-being of the infant and thorough-out life. It is therefore important to understand the factors which impact on the gut microbiome, and how the microbiota impacts on the health of the infant, in orde ppreciate how and when intervention with probiotics can be most beneficial. Many different probiotic strains have been trialled for infants, both single and multiple strains. The various studies will be reviewed for infants from birth onwards. It can be concluded that some strains have been shown to be efficacious for specific indications, and routine use for infants can be recommended for specific probiotics, but caution in the strain selection is imperative.



15:2

0-15

:45

15:2

0-15

:45

15:2

0-15

:45

CHRISTOPHE LAYSenior Scientist Gut Microbiology, Life Science Innovation – Early Life Nutrition, Danone Nutricia Research, SingaporeThe relevance of the gut microbiota in the first 1,000 days

The microbial colonization of the infant gut plays a key role in immunological and metabolic pathways, and alterations of this process have been associated with an increased susceptibility to diseases later in life. It is therefore critical to gain in-depth insights on how the early colonization process occurs and the key factors in early life that can be of long term importance. It has been previously thought that the in utero environment was largely sterile and that the fetus was not colonized with microorganisms until birth. Increasing evidence such as the presence of bacteria in the placenta, meconium or cord blood suggests that the origin and establishment of the neonatal gut microbiota begins well before delivery. This initial exposure to an antenatal source of bacteria is followed by a postnatal exposure occurring during and shortly after birth, where a larger inoculum is transferred during vaginal delivery (fecal and vaginal microbiota) and breastfeeding (human milk microbiota). Besides mode of delivery (vaginal birth vs cesarean section) and type of feeding (human milk vs formula feeding), other factors such as gestational age, introduction of solid foods, environmental factors (urban vs rural; presence of pets or siblings) and antibiotic treatment are known to influence this process. Clues from epidemiological studies have shown associations between these factors and long-term health implications.

RAMA CHAUDHRYASM International Ambassador to India; Professor, Department of Microbiology, All India Institute of Medical Sciences, IndiaExploring Indian gut microbiota in inflammatory bowel disease and colon carcinoma

Gut microbiota alteration has been associated with inflammatory bowel disease (IBD) and colorectal cancer. Sequencing technologies have recently boosted metagenomics of microbiota in human health. Since the dietary habits of Indian are different from that of Western world therefore, results of studies on Western population cannot be extrapolated to their Indian counterparts. A study has been carried out in Indian population with IBD and colon carcinoma patients. 16S ribosomal RNA amplicon sequencing has been carried out. Operational Taxonomic Units (OTUs) and relative abundance of bacteria were assessed. Control group included healthy vegetarian group and non vegetarian group. Eubacterium, Ruminococcus, Faecalibacterium, Prevotella, Bacteroides and Lactobacillus were core genera in all groups. There was significant difference in the OTUs and presence of genera and species unique to different subjects and groups.

LARRY WEISSChief Medical Officer, AOBiome, LLC, USAAmmonia Oxidizing Bacteria – A Live Topical BiotherapeuticAOBiome is exploring the role of Ammonia Oxidizing Bacteria (AOB) as an ancestral human

skin commensal. The company is developing live topical therapeutic and cosmetic formulations on Nitrosomonas Eutropha for the prevention and treatment of inflammatory disorders of the skin. This presentation will discuss discovery of AOB as skin commensals; biology of Nitrosomonas Eutropha; clinical development of AOB as a dermatologic therapeutic, and consumer products as a tool in therapeutic development.

15:4

5-16

:00

15:4

5-16

:00

15:4

5-16

:00

COMPANY SHOWCASE:SABINA LUKOVACProject Leader/Scientist Microbiota NIZO Food Research, The NetherlandsSkin microbiome in health and disease• Microbiomics screening platform• Characterization and identification of novel microbiota modulators• Dynamics of skin microbiome

COMPANY SHOWCASE:STEPHEN OHARAFounder and CEO, OptiBiotix Health plc Targeted microbiome modulation: next generation pre-, pro-, and OptiBioticsThis work reports on studies in human gut

models which have shown the ability of OptiBiotix’s microbiome modulators to increase the growth rate and biological effect of specific microbial species in the human microbiome. This has been demonstrated in multiple species, including OptiBiotix’s cholesterol reducing probiotic strain (LP-LDL®). LP-LDL® has been shown to significantly reduce both total and LDL cholesterol in independent human studies.

Crude cell extracts of LP-LDL® were used to synthesize GOS (LPGOS) from lactose, which was purified, and added alone or in combination with the parent LP-LDL® strain to pH-controlled, batch cultures in the presence of cholesterol. The results show that LPGOS significantly and selectively increased Lactobacillus populations and reduced cholesterol by more than 20%. Cholesterol reduction was further enhanced by combining LPGOS with its parent LP-LD® strain, lowering cholesterol by 27%. This

COMPANY SHOWCASE:JONATHAN KRIVECEO, Civet Biosciences, Hong KongGut Microbiota Banking + Next Generation Microbiome Research

• How Microbiota Banking developed, and where do we stand today• Best practices in safety and quality• Leveraging the latest technology to do functional research of the

gut microbiomeIn 2012, a group of pioneering academics from MIT started what can be considered as the world’s first public stool microbiota bank, OpenBiome. Since then, several stool banks in multiple countries have followed this model. Civet Biosciences launched the first commercial stool bank in Hong Kong in 2016, one of the first in Asia, called the Asia Microbiota Bank (AMB). Prioritizing safety, AMB has created a proprietary screening panel of more than 60 targets to identify the healthiest stool donors possible. Further, AMB is optimizing the stool processing procedure. Civet Biosciences with the support of AMB is now preparing to launch an expansive research program to characterize the Asian



15:4

5-16

:00

15:4

5-16

:00

15:4

5-16

:00

was a threefold improvement in cholesterol reduction than that achieved by LP-LDL® alone. The biological effect correlated with Lactobacillus concentrations indicating a synergistic effect that was not observed when LP-LDL® was used in combination with a control GOS, which had no an impact on cholesterol reduction.

These studies suggest potential for:• The development of species or genera specific prebiotics

which can selectively enhance the growth and health benefits of existing probiotic products. This new product concept, called an OptiBiotic®, has the potential to enhance probiotic health benefits and provide product differentiation in the probiotic market, a market forecast to be worth more than $46.5bn by 2020 (Markets and Markets).

• Designer ingredients which can modify an individual’s current microbiome to improve health. As LPGOS is heat resistant and stable during processing this creates the opportunity to incorporate low cost, safe, cholesterol lowering ingredients, in a wide range of food products.

CONTINUED

GUT MICROBIOTA IN HEALTH & DISEASE THERAPEUTICS DEVELOPMENT PROBIOTICS CONGRESS

17:10

-17:

35

17:10

-17:

35

17:10

-17:

35

JASNA RAKONJACAssociate Professor, Institute of Fundamental Sciences, Massey University, Palmerston North, New ZealandPanning for molecular gold in microbial genomes and metagenomes using phage display technology

Microbes are engaged in complex interactions with the environment, host, and with other members of microbial community. Identification of molecular factors that mediate or modify those interactions is essential for understanding and ultimately manipulating the effect of a microbe or microbial community on the host. By screening phage display libraries derived from individual bacteria or archaea, or from microbial communities, we have identified novel surface proteins, including adhesins, some of which mediate broad inter-kingdom interactions. We demonstrate that phage display technology, combined with the recent advances in DNA sequencing technologies, provides a powerful approach for cultivation-independent discovery of molecular basis for a range of ecologically and medically important microbial interactions.

Afternoon Refreshments / Odd Numbered Poster Presentations / Scheduled One-to-One Meetings16:00-17:10

KANWALDEEP CHADHAVice President, Next Gen Pharma India Pvt. Ltd.Probiotics – The rainbow of future• Expanding horizon.• Going beyond “gut” – current evidence on Probiotics in gynecology, cancer palliative

care, skin care. • Update on IBS/IBD with respect to product specific evidence.• Importance of production site with respect on quality

of Probiotics with some case studies using established products/brands.

COLLEEN CUTCLIFFECo-Founder & CEO, Whole Biome, USATranslating the microbiomeAs various academic and commercial teams begin to develop interventions targeting the microbiome, we all find ourselves needing to

answer 2 key questions: (1) Can we change an already existing microbial ecosystem in a predictable and desired way and (2) Can we change a person’s disease or healthy state in predictable and desired ways? The keys to answering these questions lie in the interventions themselves, but also in the methods that are used to measure and monitor the microbiome. In this talk, I will share some of Whole Biome’s learnings as we begin to explore the complexity of data acquisition and analytics required to enable us to answer these 2 key questions.

gut microbiome and understand the varying profiles across country regions and phenotype cohorts, such as healthy and by disease indication. Civet hopes to build collaborations with local clinics, hospitals, universities and research institutes through our Asia Microbiome Initiative. Our core philosophy is to support indigenous growth in the microbiome space across Asia. Please consider joining our rapidly growing list of Asia Microbiome Initiative collaborators!



17:3

5-18

:00

HONGWEI ZHOUProfessor, Director, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, ChinaPopulation survey reveals regional distribution of gut microbiota with universal microbiome signatures for metabolic syndrome• We performed a cross-sectional survey of gut microbiome for 8600 individuals using

stratified randomized sampling in Guangdong Province, China.• Gut microbiome from different sampling sites obviously aggregated, and social-economic factors showed

great impact on the distribution.• Even though the baseline of gut microbiome were different from various regions, there were similar

patterns of microbiome signatures for people with metabolic syndrome from different regions.

17:3

5-18

:00

RINA AGUSTINAScientist, Southeast Asian Ministers of Education Organization Regional Center for Food and Nutrition (SEAMEO RECFON) / Pusat Kajian Gizi Regional (PKGR), Universitas Indonesia Head of Human Nutrition Research Cluster and Research Coordinator Department of Nutrition, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital, Indonesia

Advancing probiotic research in the Southeast Asia Region: updates from the probiotic working groupProbiotic research is relatively new and fast growing in the Southeast Asia (SEA). The 2nd SEA Probiotic Working Group (PWG) workshop attended by 7 countries experts from multi-disciplines and sectors was organized by SEAMEO RECFON in collaboration with Faculty of Medicine, Universitas Indonesia in Jakarta (2016). The workshop indicated that approximately 250 studies were conducted in this region with around 34 probiotic randomized controlled-trials mainly in Indonesia, Thailand, Malaysia, Singapore, Vietnam and Myanmar. The above studies focused on acute diarrhea, child growth, antibiotic-associated diarrhea, lactose intolerance, Helicobacter pylori infection, and allergic diseases. Lactobacillus sp. appears to be the most studied strain and its application are considered safe. Although probiotic products are widely marketed especially in vulnerable groups, probiotic regulations on the development of new strains, products and claims in promoting human health is limited and non-harmonized. A huge diversities of microbiota among Asian populations was reported but information on country-specific microbial genes was lacking due to complex interaction between various local diets and gut microbiota in various ethnicities, lack of laboratory facilities, and low financial research investment. The PWG recommended to initiate a multicenter studies focusing on certain outcome (acute diarrhea and respiratory diseases treatment and prevention) or strain (a combined strain(s) with/without micronutrients) with appropriate design and duration. Probiotic studies on other outcomes (immunity, inflammation or metabolic markers) and traditional fermented foods must also be conducted. The SEA microbiota mapping using metagenomics should be used as one of the most powerful approach. Advanced techniques and high quality methodology in probiotic researches are necessary. Thus, the development or harmonization of clinical trial guidelines on safety, efficacy and effectiveness of probiotics are needed for consumer protection and advancement in probiotic science in the region. Therefore, concrete networking activities and collaboration between scientists, medical associations, industries, and regulators should be further enhanced.

Chair’s Closing Remarks / End of Day One / Networking Drinks Reception18:00-19:00

CONGRESS SCHEDULE DAY 2 THURSDAY 2ND MARCH 2017


Networking Meetings & Refreshments08

:40-

09:15

KEYNOTE ADDRESS:YUAN KUN LEEAssociate Professor, Department of Microbiology, National University of SingaporeHuman microbiota: A bioresource for gene mining and microbial prospecting• Human microbiota highly concentrated and diverse, adapting to extreme ecological environment.

• Produce wide range of enzymes that react with food constituent, for food application and processing.• Produce signal molecules, which control host gene expression in local and remote organs, for

medical application and modulation of gut microbiota.

08:00-08:40

MICROBIOME CONGRESS PROBIOTICS CONGRESS

09:15

:09:

40

09:15

:09:

40

SEAN HALLMD, MBA, CFEO/MD – Medlab Clinical Ltd, AustraliaMitigating chronic disease through manipulation of the human microbiome• The role of bacteria within the microbiome is still evolving, medical understanding is increasing• There are direct relationships between Chronic Diseases and the microbiome

• Evidence supports new therapeutic roles of bacteria for patients diagnosed with NAFLD, Depression and Obesity/Pre-Diabetes.

08:4

0-09

:15

KEYNOTE ADDRESS:YASUHIRO KOGAProfessor, Tokai University School of Medicine; President, Japanese Society for Probiotic Science, JapanFunctional dyspepsia: A novel field for the introduction of probioticsFunctional dyspepsia (FD) is defined as the presence of symptoms thought to originate in

the gastrointestinal region, in the absence of any organic or systemic diseases that can explain the symptoms. Epidemiological surveys suggest that ~30% of the general population has the symptoms over the course of one year. To date no drug has definitely been approved for the treatment of FD. This lecture will mention about a clinical trial to examine the effect of a probiotic strain LG21 on the FD symptoms, which was performed using 116 FD subjects. We also speak about the structure of gastric microbiota in FD and its role in the pathophysiology of FD, which were performed using 44 healthy controls and 44 FD patients treated with LG21.

TRACK CHAIR:RAMA CHAUDHRYASM International Ambassador to India; Professor, Department of Microbiology, All India Institute of Medical Sciences, India

TRACK CHAIR:JIAN-YONG WUAssociate Professor, Department of Applied Biology & Chemical Technology, The Hong Kong Polytechnic University

SIEW NGProfessor, Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong KongGut microbiota and fecal microbiota transplantation Alterations in the intestinal microbiota is associated with several digestive diseases and systemic diseases, including clostridium difficile infections, inflammatory bowel disease,

irritable bowel syndrome, colorectal cancer, obesity, atherosclerosis, diabetes and metabolic syndrome. Faecal microbiota transplantation (FMT) represents a clinically feasible way to restore the gut microbial ecology, via infusion of intestinal microbiota from a healthy donor into a diseased recipient. FMT has proven to be a breakthrough for the treatment of recurrent Clostridium difficile infection. There are many unanswered questions regarding FMT, including donor selection and screening, routes of administration including the development of a fecal capsule, long-term safety, and regulatory issues. We will share the Chinese University of Hong Kong’s experience in FMT for digestive diseases and address the current status and future perspective of FMT for treating human diseases.

09:4

0-10

:10

NICOLE ROYPrincipal Scientist and Science Team Leader, Food Nutrition & Health, AgResearch Grasslands, Adjunct Associate Professor, Riddet Institute, Massey University, New Zealand The first 2000 days of life, a milk storyHuman milk is rich in a family of structurally diverse unconjugated glycans that are prebiotics and improve the maturation of the gastrointestinal tract among other functions. The number of oligosaccharides reported thus far in mature bovine ruminant milks is far less than the 200 different structures reported in human milk. The paucity of studies exploring the biological functions of these oligosaccharides is attributable to the limited number of efficient methods of producing oligosaccharide enriched products. This presentation will present new findings on the molecular and

physiological analyses of the host and microbiota responses to diets enriched in oligosaccharides or other milk components. It will provide new insights into this complex relationship and its relevance to growth and development in the first 2000 days of life.



PREBIOTICS & DIET R&D OUTSIDE THE GUT PROBIOTICS CONGRESS

11:2

5-11

:50

YOSHIHISA YAMASHITAProfessor & Chairperson, Section of Preventive and Public Health Dentistry, Kyushu UniversityDiagnostic value of salivary microbiome to grasp periodontal health condition and susceptibility to periodontal disease

We previously showed the association between salivary microbiome composition and oral health related factors in the study with 2,343 community-dwelling subjects. In the study, we proposed core oral OTUs composed of 72 OTUs commonly observed. On the other hand, we recently found that most of bacteria species corresponding to minor OTUs in saliva of subjects exhibiting higher phylogenetic diversity are periodontal pathogens mainly harboring in subgingival pocket. Furthermore we defined two community types (Type I and Type II) of salivary microbiome based on relative abundances of major 22 core OTUs occupying ≥1% of mean relative abundance. Type II showed close relationship with better periodontal health condition. I will discuss diagnostic value of salivary microbiome to grasp periodontal health condition and susceptibility to periodontal disease.

11:2

5-11

:50

HANI EL-NEZAMIAssociate Professor, School of Biological Sciences, The University of Hong KongLiver cancer a potential target for probiotic interventionHepatocellular carcinoma (HCC) is the sixth

most common cancer and the second leading cause of all-cancer related deaths in the world. It is a disease with poor prognosis with unsatisfactory long-term survival of patients, and thus new strategies to control this disease are warranted. This presentation describes a series of studies showing the path from laboratory-based findings in vitro and animal experiments to confirm the in vitro findings in vivo, to field studies in human subjects. The relevance of the data collected in various stages is discussed, and a proof of concept study on the interaction of well-defined probiotic bacteria with a liver cancer associated dietary contaminant will be presented.

10:0

5-10

:35

SOLUTION PROVIDER PRESENTATION:LOUISE VIGSNAESPreclinical Development Manager, Glycom A/S, DenmarkHuman milk oligosaccharides; not just for babiesHuman Milk Oligosaccharides (HMOs) are a family of complex carbohydrates found in high concentrations in human milk and which are now becoming commercially

available. HMOs have been shown in clinical studies, in both infants and adults, to specifically modulate the gut microbiota by increasing certain Bifidobacterium species and reducing certain undesirable bacteria. However, HMOs are more than a food for gut bacteria. Due to their structure, they bind detrimental bacteria and toxins and interact with epithelial cells affecting the expression of cell-surface glycans. Additionally, HMOs can improve the gut barrier, and regulate the immune system and the gut-brain axis. These properties make HMOs potential candidates for improving health and addressing conditions beyond their known functions in infants, for example in functional gastrointestinal diseases like IBS.

Morning Refreshments / Odd & Even Numbered Poster Presentations & Scheduled One-to-One Meetings10:35-11:25

11:2

5-11

:50

PETER CHI KEUNG CHEUNGProfessor, Food and Nutritional Sciences Program, School of Life Sciences, Director, The Chinese University of Hong KongBeta-Glucans as novel prebiotics and their effects in mouse microbiome modulation

Long chain beta-glucans from mushrooms and plants are non-digestible carbohydrates with potential to be prebiotics 16S rDNA sequencing of fecal samples from BALB/c mice fed with beta-glucans indicated shift of the mouse gut microbiome with an increase of Bifidobacterium population. Beta-glucans confer beneficial effects to the host via directly by immune-stimulatory effects and indirectly via the modulation of gut microbiome.

ROUNDTABLE DISCUSSIONS:

TABLE 1: MARGARET IPProfessor, Department of Microbiology, The Chinese University of Hong KongAntimicrobial resistanceIn September 2016, the United Nations (UN) General Assembly highlighted the problem of

antimicrobial resistance (AMR) and the action plans underpin the need to understand the scale of the problem and stop misuse of antimicrobials in human, animal health and agriculture. • What is antimicrobial resistance?• How do antimicrobials impact on our human microbiota?• Can we harness innovative approaches to tackling infections via

modulation of our microbiota?

TABLE 2: YING-CHIEH TSAIProfessor, National Yang Ming University, TaiwanGut-brain axis• How does the microbiota influence brain, behavior,

and the development of neurological disorders?• What are the mechanisms behind

psychobiotics and their effect on the MGBA?• How can we bridge the gap between research and clinical

application for treatment in humans?

TABLE 3: LARRY WEISSChief Medical Officer, AOBiome, LLC, USASkin microbiome

TABLE 4: NIRANJAN NAGARAJANAssociate Director and Group Leader, Genome Institute of Singapore, A*STAR, SingaporeMicrobiome data analysis – establishing correlation & causation• 16S versus Metagenomic sequencing

▷ Poll on what is more widely used▷ Provocative questions: Should we stop using 16Ssequencing? Is metagenomic sequencing data overload?

Is there any utility for long-read platforms?• Correlation versus causation in Microbiome Research

▷ Is this a valid criticism? If so, how do we go about addressing this (longitudinal studies?, multi-omics?)▷ What are the missing bioinformatics solutions?

• What do you believe is the single biggest bioinformatics challenge in Microbiome research▷ Can we ever build true “systems biology” models? Can we predict microbial community dynamics?

• Nature versus nurture: what shapes the microbiome more, genetics or environment?



11:5

0-12

:40

11:5

0-12

:15

11:5

0-12

:40

ROUNDTABLE DISCUSSIONS:

TABLE 5: PRAMOD GOPALScience Group Leader, Food, Nutrition & Health, The NZ Institute for Plant & Food Research Ltd.Prebiotics, diet and microbiota• Prebiotics in early childhood nutrition• Prebiotics effects in the context of background habitual diets• What will be the next generation of prebiotics?

TABLE 6: SEAN HALLMD, MBA, CFEO/MD – Medlab Clinical Ltd, AustraliaBusiness development and regulation• What is the attraction to research in this area?• What are some of the major stumbling blocks in conducting research in this area?

TABLE 7: HARJINDER SINGHDistinguished Professor and Director, Massey Institute of Food Science and Technology, Massey University, New ZealandProbiotics delivery – encapsulation, survival, quality control• Challenges for the delivery of viable functional probiotic bacteria in food formulations

• Encapsulation and other technological approaches for protection of probiotics

• Protection during food processing and subsequent storage of food products

• Protection in the gastro-intestinal tract and physiological processing

RUI LI Senior Scientist, Procter & Gamble, SingaporeAn industrial perspective on oral microbiome research - using Gingivitis as an example• Why did P&G work on oral microbiome?

• What did we learn from oral microbiome research?• How are we going to apply our learning and enable innovations?

12:15

-12:

40

GILDA TACHEDJIANAssociate Professor & Principal for Sexual and Reproductive Health, Head Retroviral Biology and Antivirals Laboratory, Burnet Institute, AustraliaRole of vaginal microbiota in HIV susceptibility

• Vaginal microbiota can affect HIV risk. Vaginal lactobacilli appear to be protective while polymicrobial species (dysbiosis) is associated with increased HIV risk through promoting a pro-inflammatory environment in the cervicovaginal mucosa. Dysbiosis is also associated with reduced efficacy of female-initiated topical pre-exposure prophylaxis (PrEP) that contain HIV specific antivirals to prevent the sexual transmission of HIV.

• Vaginal lactobacilli produce lactic acid, a metabolite that has potent HIV virucidal activity and antimicrobial activity. Lactic acid also elicits the production of an anti-inflammatory cytokine and dampens the production of pro-inflammatory mediators from cervicovaginal epithelium elicited by pathogen associated molecular patterns and semen that may protect against HIV.

• Is there a role for lactic acid and/or probiotics in reversing vaginal dysbiosis/inflammation and as an adjunct for HIV PrEP?



Lunch12:55-13:55

12:4

0-12

:55

COMPANY SHOWCASE:AARON DEL DUCAVP Technology & Lead, Microbiome Program, DNA Genotek, Inc.Applying quality engineering principles to enhance reproducibility of longitudinal metagenomics studiesStudy designs for longitudinal clinical trials and for validating biospecimen collection/stabilization devices share a surprisingly common architecture. In this talk we’ll discuss the QC practises and metrics we find most helpful to identifying sources of bias in a metagenomics workflow. In particular:

• Practical considerations for establishing ‘ground truth’, and strategies for measuring small changes over time• Disentangling cause and effect when comparing longitudinal relative abundance measurements (with 16S or shotgun NGS)• In silico methods for standardized phenotyping and managing confounding variables

13:5

5-14

:25

PANEL DISCUSSION:Probiotics in animal health & aquaculture

PANEL CHAIR:ROBERT MOOREDirector, Australian Centre for Ecogenomics; Professor, School of Chemistry & Molecular Biosciences, The University of Queensland, Australia

PANELLIST:SUNEE NITISINPRASERTAssociate Professor, Department of Biotechnology, Faculty of Agro-Industry, Kasetsart University, Thailand

PANELLIST:HAU-YANG TSENProfessor of Food Science and Technology, Hungkuang University, Taiwan

PANELLIST:SHIVANANDA MURTHYProfessor & Head, Karnataka Veterinary & Fisheries Sciences University, College of Fisheries, Mangalore, India

13:5

5-14

:25

SOLUTION PROVIDER PRESENTATION:DAVID J. KYLECEO, Evolve BioSystemsThe Infant Gut Microbiome: From Dysbiosis to RecoveryHuman milk has been the sole source of nutrition for infants for millions of years, and is rich in species specific oligosaccharides (HMO). Not surprisingly, the infant

gut microbiome is dominated by a species of Bifidobacteria exceptionally well suited to consume HMOs. Through the unintended consequences of formula feeding, antibiotic use, and C-section deliveries, this natural infant microbiome has been radically changed in much of the world today. This gut dysbiosis leads to significant changes in the colonic microenvironment and may result in the increased prevalence of autoimmune and metabolic dysfunction seen over the past 60 years. We have developed a solution to rescue the natural microbiome from this dysbiosis through early intervention in healthy infants, returning the colonic microenvironment to its natural state.

PREBIOTICS & DIET PROBIOTICS IN ANIMAL HEALTH & AQUACULTURE

TRACK CHAIR:INGRID SURONOHead of Food Technology Department, Binus University, Indonesia


14:2

5-14

:50

14:2

5-14

:50

ROBERT MOOREResearch Professor of Biotechnology, RMIT University, Melbourne, AustraliaAre in vitro assays of value in assessing potentially probiotic strains of bacteria?In vitro assays have been widely used to screen collections of bacterial strains for properties that are believed to indicate the potential in vivo merits of probiotics.

Assays that are routinely used include resistance to acid and bile, adhesion to cultured eukaryotic cells, and production of antimicrobial compounds. Surprising, there is little formal proof that performance in such assays is linked to probiotic performance in vivo. The presentation will explore this issue and ask if there are more effective ways to identify probiotic bacteria by directly screening strain collections in vivo.

MARGARET MORRISProfessor, Chair and Head of Pharmacology, School of Medical Sciences, University of New South Wales, AustraliaEffects of diet on cognition – role of the microbiotaRats exposed to diets rich in either fat and sugar, or sugar, showed cognitive impairment – specifically on hippocampal-dependent place recognition memory. Changes in gut

microbiota are observed in response to such diets, with reduced diversity. Even short term exposure to diets rich in sugar or saturated fat, in the absence of weight gain, impaired cognition. The sugar- and fat-enriched diets had specific effects on the fecal microbiome. Changes in microbiota profile were associated with altered hippocampal mRNA expression of inflammatory markers.

15:15

-15:

40

14:5

0-15

:15

ROSHADA HASHIMProfessor, Fish Nutrition and Feeding Management, Faculty of Science and Technology, Universiti Sains Islam, MalaysiaOpportunities in probiotic intervention for warm freshwater fish aquacultureProbiotic supplementation in fish feeds is now widely accepted as a possible solution to address the emergence of a large variety of pathogens and bacterial resistance

caused by the indiscriminate use of chemotherapeutic agents in fish health management. However, little attention is given to understand how probiotics improve growth and nutrient utilization in diets specifically in feeds containing plant based proteins. This presentation will highlight how probiotic intake enhances growth by influencing digestive enzyme activities, gut morphology and microbiota in Channa straita and Pangasianodon hypopthalmus fingerlings compared to prebiotics. It also discusses how long the advantages attained from probiotic intake is retained and if growth can be further enhanced when a combination of probiotics and prebiotics is used. These will provide a basis for the feeding management of these two species in the future. Finally, the sustainability of probiotics to overcome the drawbacks of intensive aquaculture will be discussed.

15:15

-15:

40

HAU-YANG TSENProfessor of Food Science and Technology, Hungkuang University, TaiwanThe Development of Live and Heat Killed Probiotic with Multiple Functions for Animal Feed UseProbiotics are live organisms that may beneficially affect the host upon ingestion. The major strains with probiotic functions are those of lactic acid bacteria (LAB). These

strains may enhance the immunomodulatory activity of the host and are able to protect the host against the infection of pathogenic bacteria. Selection of the strains for animal feed use and preserving its beneficial functions after feed processing is important.: Previously, we have selected four LAB strains with basic probiotic properties and high immunomodulatory activities from 140 strains of different origins. Examples for feed supplement use of these strains include: (1). The multistrain combination of these four LAB strains, i.e., MLAB, when fed mice or chicks, was able to enhance the immunomodulatory activity of their host animals. Furthermore, this MLAB was able to reduce the invasion of pathogenic bacteria, such as the invasion of Salmonella to the liver and spleen of mice and broiler chicks, and also reduce the induced inflammation of the host animals. (2). In addition, it was able to ameliorate the growth rate and the inflammation of broiler chicks caused by Eimeria tenella infection. (3). Moreover, it was also able to enhance the growth rate and the antibody production in chicks vaccinated with New Castle Disease Virus (NCDV). (4). Heat killed cells of this MLAB or the individual strains of this MLAB also has similar functions, which is important for feed processing use. One of the individual strains of this MLAB also has been proved to be useful for pig feed supplement use. Thus this MLAB has multiple beneficial functions when used as the feed supplement.

ELIANA MARIÑOHead, Immunology and Diabetes Laboratory, Monash University, Melbourne, AustraliaGut microbial metabolites regulate autoimmune T cell responses and protect against type 1 diabetesDiet and gut microbial ecology may underlie the increasing incidence of certain inflammatory diseases. Here, we found that key features of autoimmune diabetes in

NOD mice correlated closely with fecal concentrations of the short chain fatty acids (SCFAs) acetate and butyrate. High acetate- or butyrate-yielding diets significantly reduced progression to diabetes, towards changes in the microbial community, improved gut epithelial integrity and reduced concentrations of pro-inflammatory cytokines. Both acetate and butyrate diets led to dramatically decreased numbers of autoreactive T cells. A high butyrate-yielding diet promoted conversion of naïve Foxp3- T cells into Foxp3+ Treg cells in vivo. In contrast, an acetate-yielding diet directly targeted B cells, which led to a markedly control of autoimmune T cell frequencies, and protection from diabetes.

Conference Close15:40

14:5

0-15

:15

YUNN-HWEN GANAssociate Professor, Department of Biochemistry, National University of SingaporeDifferential host and bacterial virulence factors driving Klebsiella liver abscess in ethnically diverse SingaporeHypervirulent Klebsiella pneumoniae is an emerging cause of community-acquired pyogenic liver abscess in parts of Asia such as South Korea, Singapore, Taiwan and

Hong Kong. The bacteria are believed to translocate from the intestines to the liver. However, factors which predispose and facilitate the colonisation in the gut are not clearly understood. We examined prospectively the profiles of 70 patients together with their isolates’ genotypic and phenotypic characteristics in ethnically diverse Singapore. The majority of isolates belonged to capsule type K1, which carried higher frequencies of virulence-associated genes. The Chinese, mostly non-diabetic, had higher prevalence of K1 infection than the predominantly diabetic non-Chinese. We also study the nutritional and colonization requirements of various isolates in the gut to understand the link to disease.


CONGRESS SCHEDULE

MAKING A POSTER PRESENTATIONPoster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters.

We also issue a poster eBook to all attendees with your full abstract in and can share your poster as a PDF after the meeting if you desire (optional).

Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.

In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration).

We charge an admin fee of $100 to industry delegates to present, that goes towards the shared cost of providing the poster presentation area and display boards, guides etc. This fee is waived for those representing academic institutions and not for profit organisations.

POSTER PRESENTATIONS:

VENUE HONG KONG:

Having been in Kuala Lumpur, Malaysia for 3 years in a row, the congress is moving to Hong Kong for the first time!

The Eaton Hotel, in the heart of electric Kowloon.

Eaton Hotel, 380 Nathan Road, Kowloon, Hong Kongwww.eatonhongkong.com/en/hotel

T: +60 3 2117 5193E: [email protected]

Follow Us

Asia Pacific Office, Global Engage Sdn Bhd, Level 33, Inham Tower, No. 8 Jalan Binjai, 50450 Kuala Lumpur, Malaysia

SPONSORSHIP AND EXHIBITION OPPORTUNITIES AVAILABLEFor more details contact Shahul Hameed:

[email protected]: +60 3 2117 5196 Cell: +60 1 6656 4828

DON’T DELAY, BOOK YOUR PLACE TODAY!Places are limited and are based on a first come, first served basis so to avoid disappointment contact us today to reserve

your place at Global Engage’s Microbiome R&D and Business Collaboration Congress Asia 2017 on the 1st-2nd March.

PHONE BOOKING+60 3 2117 5193

Our conference team will make all the necessary arrangements.

ONLINE BOOKINGVisit the website to book your place with credit card payment or an invoice request.

www.global-engage.com/event/microbiome-asia/

THE CONGRESS PACKAGE INCLUDES:All Conference Sessions

Lunches and RefreshmentsAccess to Exhibition Room

Networking Drinks ReceptionConference Workbook

E-Document Pack

HOTEL ACCOMMODATIONHotel accommodation will be available at a group rate.

FREE NEWSLETTERFor updates on the Microbiome R&D and Business Collaboration Congress Asia 2017, plus free resources

and reports, as and when our speakers authorise their release dates, check for updates at:www.global-engage.com/event/microbiome-asia/

UNABLE TO MAKE THE DATES?Why not sign up for either our European or US meeting

Europe: 3-4 April 2017 – Amsterdam, The Netherlands www.global-engage.com/event/microbiota/USA: 2-3 November 2017 – San Diego www.global-engage.com/event/microbiome/

Documents

GLOBAL ENGAGE’S 3 MICROBIOME R&D AND …€¦ · a therapeutics market that is expected to grow to $1.2 trillion by 2016, ... Yakult Danone India Pvt. Ltd. ... • Feed additives